<DOC>
	<DOC>NCT00027391</DOC>
	<brief_summary>This is a study to determine whether albuterol or oxandrolone, alone or in combination, are able to increase strength and muscle mass in patients with FSHD. It also will determine if albuterol given in "pulsed" fashion will have more effect than when given continuously.</brief_summary>
	<brief_title>Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)</brief_title>
	<detailed_description>Patients will be randomized to 1 of 4 groups: placebo, pulsed albuterol, oxandrolone, or both pulsed albuterol and oxandrolone. Treatment will continue for 52 weeks unless unacceptable side effects occur. Patients will undergo testing of muscle function. All patients will return for follow-up assessments at Weeks 4, 12, 26, and 52.</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Oxandrolone</mesh_term>
	<criteria>Inclusion criteria: Presence of 4q35 "small fragment" of less than 40 kb by standard DNA testing Weakness of the facial muscles, including frontalis, orbicularis oculi, or orbicularis oris Weakness of scapular stabilizers or foot dorsiflexors Ambulatory Weakness grade 2 or worse in the arm using upper extremity grading scale Exclusion criteria: Prior use of oral beta2 agonists for a period of at least 1 year or within the past 3 months Concurrent use of other sympathomimetic agents, antidepressants, or beta2 receptor blockers Pregnancy Known hypersensitivity to anabolic steroids Any medical or psychological condition that would interfere with the study Requirement for a wheelchair</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>Muscle Weakness, Muscular Dystrophy</keyword>
</DOC>